Dyslipidemia in primary care – prevalence, recognition, treatment and control: data from the German Metabolic and Cardiovascular Risk Project (GEMCAS)

Steinhagen-Thiessen, Elisabeth; Bramlage, Peter; Lösch, Christian; Hauner, Hans; Schunkert, Heribert; Vogt, Anja; Wasem, Jürgen; Jöckel, Karl-Heinz; Moebus, Susanne

doi:10.1186/1475-2840-7-31

Cardiovascular Diabetology

Table 3 Comparison of patients with a) known vs. unknown dyslipidemia; b) controlled without pharmacotherapy (drugs) vs. uncontrolled and c) controlled with pharmacotherapy (drugs) vs. uncontrolled

From: Dyslipidemia in primary care – prevalence, recognition, treatment and control: data from the German Metabolic and Cardiovascular Risk Project (GEMCAS)

	Known vs. unknown dyslipidemia			Controlled without drugs vs. uncontrolled			Controlled with drugs vs. uncontrolled
	N	PRR	95%CI	N	PRR	95%CI	N	PRR	95%CI
Male gender vs. female	5 296	1.15¹	1.12;1.17	181	2.00¹	1.60;2.50	663	1.30¹	1.67;1.44
Age > 65 years vs. ≤ 65	4 485	1.68²	1.64;1.72	110	0.97²	0.78;1.22	569	1.14²	1.03;1.26
Risk factors
Type-2-Diabetes vs. none	2 840	1.51	1.44;1.58	137	1.37	1.10;1.72	463	0.95	0.86;1.05
Hypertension (140/90) vs. no	3 995	1.70	1.65;1.76	104	1.06	0.83;1.35	337	1.20	1.05;1.37
BMI ≥ 30 vs. < 25 kg/m²	3 999	1.48	1.42;1.53	134	1.15	0.87;1.54	361	0.84	0.73;0.97
WC > 102/88 cm vs. normal	6 400	1.50	1.44;1.56	187	0.99	0.76;1.30	588	0.77	0.68;0.87
Co-morbid disease
CVD vs. no	3 609	1.45	1.41;1.50	121	1.34	1.06;1.70	770	1.46	1.29;1.64
MI vs. no	1 695	1.24	1.20;1.29	46	1.48	1.09;2.01	494	1.32	1.19;1.47
Stroke vs. no	607	1.26	1.16;1.37	18	1.08	0.69;1.71	139	1.08	0.93;1.25
PAD vs. no	621	1.33	1.22;1.44	21	1.17	0.76;1.79	147	1.07	0.93;1.24
Heart Failure vs. no	1 284	1.05	1.02;1.08	52	1.78	1.32;2.40	241	1.11	0.98;1.25
Liver disease vs. no	1 436	1.57	1.47;1.68	56	1.29	0.95;1.75	144	0.94	0.79;1.11
Patient self reported
School < 10 years vs. ≥ 10	6 751	1.14	1.11;1.18	181	1.17	0.92;1.48	633	0.89	0.80;0.99
Apprenticeship vs. > Appr.	9 138	1.06	1.02;1.11	244	1.62	1.07;2.47	789	0.80	0.70;0.91
Hypertension vs. no	6 668	1.56	1.51;1.61	180	1.17	0.92;1.49	768	1.18	1.04;1.34
MI vs. no	1 061	1.51	1.41;1.61	36	2.13	1.53;2.96	324	1.37	1.23;1.53
Stroke vs. no	601	1.24	1.14;1.35	17	1.14	0.71;1.82	129	1.07	0.92;1.25
Diabetes vs. no	2 590	1.51	1.45;1.58	119	1.38	1.10;1.74	430	1.01	0.91;1.12
Dyslipidemia vs. no	7 928	3.80	3.64;3.96	145	0.59	0.46;0.75	741	0.70	0.61;0.79
Liver vs. no	933	1.18	1.14;1.21	29	1.10	0.77;1.59	86	1.01	0.84;1.21
Kidney vs. no	968	1.01	0.98;1.03	26	1.14	0.77;1.67	103	1.01	0.86;1.20
Rheuma vs. no	1 235	1.04	1.02;1.06	30	1.15	0.80;1.66	103	0.91	0.76;1.08
Cancer vs. no	917	0.98	0.94;1.02	26	1.23	0.83;1.81	86	1.01	0.84;1.21
Arthrosis vs. no	4 543	1.10	1.07;1.13	97	0.95	0.74;1.22	398	0.87	0.77;0.97
Sports > 4 h vs. ≤ 4 h	941	1.06	1.01;1.12	22	1.05	0.70;1.59	98	0.87	0.74;1.03
Dyspnea on stairs vs. none	5 413	1.12	1.07.1.16	144	1.82	1.05;3.17	544	0.83	0.63;1.10
Smoking ever vs. never	6 222	1.06	1.04;1.09	178	1.16	0.91;1.48	585	0.87	0.78;0.97
Diet many vs. none	343	1.50	1.35;1.68	10	1.39	0.75;2.60	24	0.90	0.64;1.29

PRR, prevalence rate ratios adjusted for age and gender; ¹ only age adjusted, ²only sex adjusted

Back to article page

ISSN: 1475-2840

Contact us

Submission enquiries: journalsubmissions@springernature.com